Janux Therapeutics (NASDAQ:JANX) Full Year 2024 Results
Key Financial Results
- Revenue: US$10.6m (up 31% from FY 2023).
- Net loss: US$69.0m (loss widened by 18% from FY 2023).
- US$1.28 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Janux Therapeutics EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 15%. Earnings per share (EPS) exceeded analyst estimates by 2.7%.
Looking ahead, revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are down 8.7% from a week ago.
Risk Analysis
It's necessary to consider the ever-present spectre of investment risk. We've identified 4 warning signs with Janux Therapeutics (at least 1 which is concerning), and understanding them should be part of your investment process.
Valuation is complex, but we're here to simplify it.
Discover if Janux Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.